<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461019</url>
  </required_header>
  <id_info>
    <org_study_id>CF-MS-01</org_study_id>
    <nct_id>NCT00461019</nct_id>
  </id_info>
  <brief_title>CardioFit™ for the Treatment of Heart Failure</brief_title>
  <official_title>CardioFiT™ for Heart Failure - Safety and Efficacy Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioControl Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioControl Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congestive Heart Failure is the result of a number of diseases affecting the heart, causing&#xD;
      the heart's failure to properly meet the body demands for blood circulation. In spite of&#xD;
      advances in drug therapy, it remains a significant public health problem.&#xD;
&#xD;
      Pharmacologic antagonism of the beta-adrenergic receptors shifting the autonomic balance in&#xD;
      the direction of greater vagal influence is a well-proven treatment for heart failure&#xD;
      patients, although there are patients who cannot tolerate, or only partially benefit from&#xD;
      such a treatment.&#xD;
&#xD;
      It has been proven in the past and well established that parasympathetic nerve stimulation&#xD;
      can slow the rate of the heart and reduce the workload of the heart. Therefore, the potential&#xD;
      benefit of vagus nerve stimulation, hence parasympathetic activation, for treatment of heart&#xD;
      failure is substantial.&#xD;
&#xD;
      In this study, the safety and efficacy of a new vagus nerve stimulating system will be&#xD;
      evaluated. This study will compare whether the new device improves Heart Failure parameters&#xD;
      in Class II - III Heart Failure patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Purpose of the study: To determine the safety and efficacy of the CardioFit™ system for&#xD;
           treatment of Class II-III Heart Failure patients.&#xD;
&#xD;
        -  Study hypothesis: CardioFit system treatment will improve patients Heart Failure&#xD;
           parameters.&#xD;
&#xD;
        -  Tested hypothesis: Thirty patients are required to provide 80% power at 95% confidence&#xD;
           level in order to detect 12 points difference on a quality of life questionnaire between&#xD;
           pre- and post activation.&#xD;
&#xD;
        -  Design: Prospective, self-controlled interventional study composed of 5 periods:&#xD;
           Pre-implantation, Implantation, Device activation, Follow-up (with active device) and&#xD;
           post-study extension period.&#xD;
&#xD;
        -  Study duration is 7.5-months per patient. At the end of the study, patients enter an&#xD;
           extension period (with active devices) during which they will be monitored for quality&#xD;
           of life and survival, for up to 3 years post-implantation in 6-months intervals.&#xD;
&#xD;
        -  Study Endpoints:&#xD;
&#xD;
             -  Primary endpoints: The occurrence of all system and/or procedure related adverse&#xD;
                events.&#xD;
&#xD;
             -  Secondary endpoints: changes in the following individual variables as well as in a&#xD;
                composite score of individual variables change: NYHA class; Quality of Life;&#xD;
                Exercise capacity (by 6-min walk); LV Ejection fraction; LV end-systolic and&#xD;
                end-diastolic volumes; blood tests.&#xD;
&#xD;
        -  Up to 10 participating centers in Europe, Israel and Australia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of all system and/or procedure related adverse events.</measure>
    <time_frame>along the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA class</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity (by 6-min walk)</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Ejection fraction</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV end-systolic and end-diastolic volumes</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood tests.</measure>
    <time_frame>At 6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Implantation of the CardioFit system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantation and activation of the vagus nerve stimulator</intervention_name>
    <description>Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead</description>
    <arm_group_label>Implantation of the CardioFit system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is in chronic heart failure, NYHA II-III. The patient may have been&#xD;
             previously in class IV but must be in class II or III for three or more months prior&#xD;
             to study entry;&#xD;
&#xD;
          2. Age between 18 and 75 years;&#xD;
&#xD;
          3. The patient is a male or postmenopausal female. Females of childbearing age may be&#xD;
             included if pregnancy is excluded and acceptable contraception measures are used;&#xD;
&#xD;
          4. Patient must sign an approved informed consent form. Patient agrees to attend all&#xD;
             follow-up evaluations;&#xD;
&#xD;
          5. Patient should be in sinus rhythm. Average 24-hour heart rate is between 60 and 110&#xD;
             b/min in a recorded 24-h Holter measurement;&#xD;
&#xD;
          6. Patient should be in optimal medical treatment with no change in treatment in the&#xD;
             previous 3 months with the exception of diuretics;&#xD;
&#xD;
          7. Left ventricular ejection fraction estimated by echocardiography, cardiac angiography,&#xD;
             radionuclide study, or other accepted mode of evaluation, is no more than 35%;&#xD;
&#xD;
          8. Patient is physically capable and willing to perform repeated physically demanding&#xD;
             tests associated with the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of an immediately life threatening condition or disease other than heart&#xD;
             failure, such as cancer, terminal renal failure etc.&#xD;
&#xD;
          2. Acute myocardial Infarction (MI), variant angina pectoris, unstable angina or acute&#xD;
             coronary syndrome in the previous three months;&#xD;
&#xD;
          3. Previous stroke;&#xD;
&#xD;
          4. Coronary Artery Bypass Surgery (CABG) or Percutaneous Coronary Intervention in the&#xD;
             past 3 months;&#xD;
&#xD;
          5. Episode of NYHA class IV heart failure, including acute pulmonary oedema in the&#xD;
             previous three months;&#xD;
&#xD;
          6. Heart failure due to acute myocarditis. Restrictive or constrictive pericarditis,&#xD;
             haemodynamically significant aortic valve insufficiency aortic stenosis, or mitral&#xD;
             valve stenosis;&#xD;
&#xD;
          7. Severe renal or hepatic failure (Creatinine level&gt;3 mg% (265 micromole/liter) or&#xD;
             transaminase level four times ULN);&#xD;
&#xD;
          8. Diabetes Mellitus treated with insulin for more than two years prior to study entry;&#xD;
&#xD;
          9. Diabetic neuropathy;&#xD;
&#xD;
         10. Previous neck surgery, including for Peripheral Vascular Disease (PVD), malignancy,&#xD;
             and previous irradiation therapy of the neck;&#xD;
&#xD;
         11. Current hypotension (systolic blood pressure below 80 mmHg);&#xD;
&#xD;
         12. Active peptic disease or history of upper GI bleeding;&#xD;
&#xD;
         13. Asthma, severe COPD (e.g. FEV1&lt;1.5 liter), or severe restrictive lung disease;&#xD;
&#xD;
         14. 1st degree AV block with PR interval &gt; 240msec, 2nd or 3rd degree AV block;&#xD;
&#xD;
         15. Atrial fibrillation or flutter in the in the previous 3 months;&#xD;
&#xD;
         16. Sustained ventricular tachyarrhythmia with hemodynamic compromise, in the absence of&#xD;
             implanted ICD;&#xD;
&#xD;
         17. Long QT syndrome, congenital or acquired;&#xD;
&#xD;
         18. Recorded or suspected symptomatic vaso-vagal response;&#xD;
&#xD;
         19. Treatment by investigational drug or device within the past 3 months;&#xD;
&#xD;
         20. Glaucoma, or history of glaucoma;&#xD;
&#xD;
         21. Major psychiatric disorder in the present or in the past; Dementia;&#xD;
&#xD;
         22. Patients transplanted with tissues or organs;&#xD;
&#xD;
         23. Immunosuppressed patients; patients under systemic steroid treatment;&#xD;
&#xD;
         24. Anemia with Hb&lt;10gr/L, unless treated with Epo;&#xD;
&#xD;
         25. Patients who are at risk for carotid arteries plaques and have unstable carotid&#xD;
             plaques, as assessed by Echo Doppler; and/or patients with &gt;70% carotid artery&#xD;
             stenosis;&#xD;
&#xD;
         26. Patient is candidate for cardiac resynchronization device implantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Schwartz, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San-Matteo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georg-August-Universität Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto von-Guericke University Clinik</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik, Klinikum Mannheim GmbH Universitätsklinikum Fakultät für klinische Medizin Mannheim der Universität Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico &quot;San Matteo&quot;</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacemaker center, Cardiovascular institute Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Former Serbia and Montenegro</country>
    <country>Israel</country>
  </removed_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/show/NCT01303718?term=BioControl+Medical&amp;rank=1</url>
    <description>INOVATE-HF INcrease Of VAgal TonE in Heart Failure</description>
  </link>
  <results_reference>
    <citation>De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ; CardioFit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011 Apr;32(7):847-55. doi: 10.1093/eurheartj/ehq391. Epub 2010 Oct 28.</citation>
    <PMID>21030409</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008 Sep;10(9):884-91. doi: 10.1016/j.ejheart.2008.07.016. Epub 2008 Aug 28.</citation>
    <PMID>18760668</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <last_update_submitted>March 4, 2011</last_update_submitted>
  <last_update_submitted_qc>March 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sponsor</name_title>
    <organization>BioControl Medical (B.C.M) Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

